Should the vaccine strain be changed?
If its composition is modified for boosters, should it also be done for primary vaccinations?
Or should we wait for more data?
The American drug agency (FDA) debated all these questions on Tuesday.
Its special committee examined the information provided by the laboratories, in particular Pfizer/BioNTech and Moderna, concerning their vaccines adapted to the Omicron variant.
With one goal and one hope: to have more effective products in the coming weeks and months.
Subscribe to read more
Already subscribed?
To log in
